The pharmacological and biological importance of EZH2 signaling in lung cancer

被引:12
作者
Entezari, Maliheh [1 ,2 ]
Taheriazam, Afshin [1 ,3 ]
Paskeh, Mahshid Deldar Abad [1 ,2 ]
Sabouni, Eisa [4 ]
Zandieh, Mohammad Arad [5 ]
Aboutalebi, Maryam [1 ]
Kakavand, Amirabbas [1 ]
Rezaei, Shamin [1 ]
Hejazi, Elahe Sadat [1 ]
Saebfar, Hamidreza [6 ]
Salimimoghadam, Shokooh [7 ]
Mirzaei, Sepideh [8 ]
Hashemi, Mehrdad [1 ,2 ]
Samarghandian, Saeed [9 ]
机构
[1] Islamic Azad Univ, Farhikhtegan Hosp Tehran Med Sci, Farhikhtegan Med Convergence Sci Res Ctr, Tehran, Iran
[2] Islamic Azad Univ, Fac Adv Sci & Technol, Dept Genet, Tehran Med Sci, Tehran, Iran
[3] Islamic Azad Univ, Fac Med, Tehran Med Sci, Dept Orthoped, Tehran, Iran
[4] Islamic Azad Univ, Fac Vet Med, Sci & Res Branch, Tehran, Iran
[5] Univ Tehran, Fac Vet Med, Dept Food Hyg & Qual Control, Div Epidemiol, Tehran, Iran
[6] Univ Milan, European Univ Assoc, League European Res Univ, Milan, Italy
[7] Shahid Chamran Univ Ahvaz, Fac Vet Med, Dept Biochem & Mol Biol, Ahvaz, Iran
[8] Islamic Azad Univ, Fac Sci, Dept Biol, Sci & Res Branch, Tehran, Iran
[9] Neyshabur Univ Med Sci, Hlth Ageing Res Ctr, Neyshabur, Iran
关键词
Lung cancer; EZH2; signaling; Cancer therapy; Drug resistance; Non-coding RNAs; GROUP PROTEIN EZH2; EZH2-MEDIATED EPIGENETIC SUPPRESSION; REGULATES CELL-PROLIFERATION; ADENOCARCINOMA CELLS; COLORECTAL-CANCER; IN-VITRO; METHYLTRANSFERASE EZH2; PROMOTES PROLIFERATION; CISPLATIN RESISTANCE; CONFERS RESISTANCE;
D O I
10.1016/j.biopha.2023.114313
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Up to 18% of cancer-related deaths worldwide are attributed to lung tumor and global burden of this type of cancer is ascending. Different factors are responsible for development of lung cancer such as smoking, envi-ronmental factors and genetic mutations. EZH2 is a vital protein with catalytic activity and belongs to PCR2 family. EZH2 has been implicated in regulating gene expression by binding to promoter of targets. The impor-tance of EZH2 in lung cancer is discussed in current manuscript. Activation of EZH2 significantly elevates the proliferation rate of lung cancer. Furthermore, metastasis and associated molecular mechanisms including EMT undergo activation by EZH2 in enhancing the lung cancer progression. The response of lung cancer to therapy can be significantly diminished due to EZH2 upregulation. Since EZH2 increases tumor progression, anti-cancer agents suppressing its expression reduce malignancy. In spite of significant effort in understanding modulatory function of EZH2 on other pathways, it appears that EZH2 can be also regulated and controlled by other factors that are described in current review. Therefore, translating current findings to clinic can improve treatment and management of lung cancer patients.
引用
收藏
页数:13
相关论文
共 50 条
[41]   MicroRNA-130-5p promotes invasion as well as migration of lung adenocarcinoma cells by targeting the EZH2 signaling pathway [J].
Zhang, G. ;
Wu, Y-J. ;
Yan, F. .
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2019, 23 (21) :9480-9488
[42]   M2 tumor-associated macrophage promoted DNA methylation in lung cancer metastasis via intensifying EZH2 [J].
Li, Zheming ;
Luo, Jing ;
Zhao, Kaixiang ;
Xu, Jingjing ;
Xia, Lilong .
ANTI-CANCER DRUGS, 2024, 35 (01) :22-35
[43]   Prognostic Value of TWIST1 and EZH2 Expression in Colon Cancer [J].
Raouf, Samar M. Abdel ;
Ibrahim, Taiseer R. ;
Abdelaziz, Lobna A. ;
Farid, Mohamed, I ;
Mohamed, Salem Y. .
JOURNAL OF GASTROINTESTINAL CANCER, 2021, 52 (01) :90-98
[44]   Prognostic Value of TWIST1 and EZH2 Expression in Colon Cancer [J].
Samar M. Abdel Raouf ;
Taiseer R. Ibrahim ;
Lobna A. Abdelaziz ;
Mohamed I. Farid ;
Salem Y Mohamed .
Journal of Gastrointestinal Cancer, 2021, 52 :90-98
[45]   The role of EZH2 in overall survival of colorectal cancer: a meta-analysis [J].
Vilorio-Marques, Laura ;
Martin, Vicente ;
Diez-Tascon, Cristina ;
Francisca Gonzalez-Sevilla, Maria ;
Fernandez-Villa, Tania ;
Honrado, Emiliano ;
Davila-Batista, Veronica ;
Molina, Antonio J. .
SCIENTIFIC REPORTS, 2017, 7
[46]   A missense variant in EZH2 is associated with colorectal cancer risk in a Chinese population [J].
Li, Huihui ;
Chang, Chunxiao ;
Shang, Yuhong ;
Qiang, Ling ;
Zhang, Baoxuan ;
Bu, Bing ;
Ren, Guohua ;
Song, Lihua ;
Shang, Mao ;
Yu, Jinming .
ONCOTARGET, 2017, 8 (55) :94738-94742
[47]   An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients [J].
Crea, F. ;
Fornaro, L. ;
Paolicchi, E. ;
Masi, G. ;
Frumento, P. ;
Loupakis, F. ;
Salvatore, L. ;
Cremolini, C. ;
Schirripa, M. ;
Graziano, F. ;
Ronzoni, M. ;
Ricci, V. ;
Farrar, W. L. ;
Falcone, A. ;
Danesi, R. .
ANNALS OF ONCOLOGY, 2012, 23 (05) :1207-1213
[48]   LINC00565 promotes the progression of colorectal cancer by upregulating EZH2 [J].
Shao, Xiaxia ;
Zhao, Tao ;
Xi, Lei ;
Zhang, Yuhong ;
He, Jia ;
Zeng, Jie ;
Deng, Lichun .
ONCOLOGY LETTERS, 2021, 21 (01)
[49]   Enhancer zeste homolog 2 (EZH2) targeting by small interfering RNA (siRNA); recent advances and prospect [J].
Hsu, Chou-Yi ;
Mohammed, Abdulsalam Najm ;
Hjazi, Ahmed ;
Uthirapathy, Subasini ;
Renuka, Jyothi S. ;
Singh, Abhayveer ;
Thyagarajan, Subhashree ;
Ray, Subhashree ;
Hulail, Hanen Mahmod .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2025, 398 (07) :7949-7970
[50]   Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells [J].
Takashina, Taichi ;
Kinoshita, Ichiro ;
Kikuchi, Junko ;
Shimizu, Yasushi ;
Sakakibara-Konishi, Jun ;
Oizumi, Satoshi ;
Nishimura, Masaharu ;
Dosaka-Akita, Hirotoshi .
CANCER SCIENCE, 2016, 107 (07) :955-962